The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients

scientific article

The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID10919581

P2093author name stringMcDiarmid SV
Ament ME
Busuttil RW
Vargas JH
Goss JA
Martin MG
Younes BS
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectimmunosuppressionQ1455316
P304page(s)94-99
P577publication date2000-07-01
P1433published inTransplantationQ15730500
P1476titleThe effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients
P478volume70

Reverse relations

cites work (P2860)
Q34733329Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience
Q35108227Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment
Q37450543Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)
Q92608218Incidence of Neoplasia in Pigs and Its Relevance to Clinical Organ Xenotransplantation
Q33870724Long-term results of pediatric liver transplantation in a combined pediatric and adult transplant program.
Q33346685Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence
Q42053532Lowered Immune Cell Function in Liver Recipients Recovered From Posttransplant Lymphoproliferative Disease Who Developed Graft Tolerance.
Q37824825Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options
Q38032320Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens
Q37145738Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation.
Q52739813Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy.
Q26798306Neoplastic disease after liver transplantation: Focus on de novo neoplasms
Q83364643Pediatric liver transplantation
Q37577733Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation
Q26780262Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?
Q44170861Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience
Q90449698Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder
Q35147068Tacrolimus: a further update of its use in the management of organ transplantation
Q41219311The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder
Q35045949Therapy for acute rejection in pediatric organ transplant recipients
Q58572650Will donor-derived neoplasia be problematic after clinical pig organ or cell xenotransplantation?

Search more.